SMARCA1 and breast cancer: The inhibitory effect on ITGA3 and SMARCA1 is in line with the observed phenotypic effects since silencing of ITGA3 has previously been shown to diminish the migratory capacity of colorectal cancer cells, whereas growth inhibition and increased apoptosis have been reported in breast cancer cell lines after SMARCA1 knock-down40–42.